GLF
VERV

Groupe la Francaise’s Verve Therapeutics VERV Stock Holding History

Groupe la Francaise’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-95,400
Closed -$1.07M – 824
2025
Q2 		$1.07M Buy
+95,400
New +$544K 0.02% 260

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Groupe la Francaise's VERV Position: Q3 2025 in Review

Groupe la Francaise sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 95,400 shares — an estimated $1.07M sold.

Groupe la Francaise first reported a position in VERV in Q2 2025 and held it in 1 quarter. The position peaked at $1.07M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Groupe la Francaise reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Groupe la Francaise sold 95,400 Verve Therapeutics shares in Q3 2025, an estimated $1.07M.
  • Groupe la Francaise first reported a position in Verve Therapeutics in Q2 2025 and held it in 1 quarter.
  • Groupe la Francaise's Verve Therapeutics position peaked at $1.07M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Groupe la Francaise's 13F filing for Q3 2025, filed 13 Nov 2025.